Evidence map›Paper›PMID 30143046›Full record

Trial reportBMC veterinary research2018

Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma.

Abbey R Sadowski, Heather L Gardner, Antonella Borgatti, Heather Wilson, David M Vail, Joshua Lachowicz, Christina Manley, Avenelle Turner, Mary K Klein, Angharad Waite and 2 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC veterinary research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Second era of molecular-targeted cancer therapies in dogs.The Journal of veterinary medical science · 2023
    Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Abbey R SadowskiCummings School, Tufts University, Foster Hospital for Small Animals, 200 Westboro Rd, N. Grafton, MA, 01536, USA.
Heather L GardnerSackler School of Graduate Biomedical Sciences, Tufts University, Boston, MA, USA.
Antonella BorgattiCollege of Veterinary Medicine, University of Minnesota, St. Paul, MN, USA.
Heather WilsonCollege of Veterinary Medicine, Texas A&M University, College Station, TX, USA.
David M VailDepartment of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Joshua LachowiczNYC Veterinary Specialists/Blue Pearl Veterinary Specialists, New York, NY, USA.
Christina ManleyThe Oncology Service, The LifeCentre, Leesburg, VA, USA.
Avenelle TurnerVeterinary Cancer Group, Culver City, CA, USA.
Mary K KleinSouthern Arizona Veterinary Specialty and Emergency Center, Tucson, AZ, USA.
Angharad WaiteThe Oncology Service, Dogwood Veterinary Emergency and Specialty Center, Richmond, VA, USA.
Alexandra SahoraThe Oncology Service, Friendship Hospital for Animals, Washington DC, USA.
Cheryl A LondonCummings School, Tufts University, Foster Hospital for Small Animals, 200 Westboro Rd, N. Grafton, MA, 01536, USA. Cheryl.London@tufts.edu.ORCID http://orcid.org/0000-0001-8563-1490

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
The Ohio State University Center for clinical and Translational ScienceUL1TR001070 · NCATS · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2013 to 2017
$22.6M
NCATS NIH HHS UL1 TR001070NCI NIH HHS P30 CA016058
6 · The paper itself

Abstract

backgroundChemotherapeutic options for the treatment of canine lymphoma have not changed in several decades necessitating the identification of new therapeutics to improve patient outcome. KPT-335 (verdinexor) is a novel orally bioavailable selective inhibitor of nuclear export (SINE) that exhibited anti-tumor activity against non-Hodgkin lymphoma in a prior phase I study. The objective of this phase II study was to expand upon the initial findings and assess the activity and safety in a larger population of dogs with lymphoma.

resultsFifty-eight dogs with naïve or progressive B-cell and T-cell lymphoma were enrolled in this clinical trial. KPT-335 was administered orally in one of three dosing groups, based on the previously established biologically active dose of 1.5 mg/kg three times weekly. Treatment with single-agent, orally administered KPT-335 resulted in an objective response rate (ORR) of 37%, of which dogs with T-cell lymphoma had an ORR of 71%. KPT-335 was well tolerated in all dose groups with grade 1-2 anorexia being the most common adverse event. Anorexia was responsive to symptomatic and supportive medications, including prednisone.

conclusionsThese data demonstrate that KPT-335 has biologic activity in canine lymphoma, and support continued evaluation of SINE compounds such as KPT-335 in combination with standard chemotherapeutics in canine lymphoma.

Indexed as

AcrylamidesActive Transport, Cell NucleusAdministration, OralAnimalsAnorexiaAntineoplastic AgentsDogsDose-Response Relationship, DrugFemaleHydrazinesLymphomaMaleTriazolesAcrylamidesAntineoplastic AgentsHydrazinesTriazolesverdinexorAnti-tumor agentClinical trialNon-Hodgkin lymphomaNuclear export

Identifiers

PMID30143046
PMCPMC6109271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.